Learning Objective 1:Recognize the role of adjuvant systemic therapy for resected lung cancer.
Learning Objective 2:Understand some of the unique toxicities of the small molecule tyrosine kinase inhibitors in use for lung cancer treatment.
Learning Objective 3:Appreciate the role of immune checkpoint inhibitors in lung cancer management
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation